The risks and benefits of antidepressants to treat pediatric-onset depression and anxiety disorders: A developmental perspective

Psychotherapy and Psychosomatics

Volumn 82, Issue 3, 2013, Pages 129-131

  Leckman, James F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SERTRALINE;

ANXIETY DISORDER; ATTRIBUTABLE RISK; CHILDHOOD; CHILDHOOD DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; DEPRESSION; DRUG INDUSTRY; EDITORIAL; EMOTIONAL DISORDER; FAMILY HISTORY; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MANIA; ONSET AGE; PEDIATRICIAN; PLACEBO EFFECT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SUICIDAL IDEATION; SYSTEMATIC REVIEW (TOPIC);

EID: 84875668907     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000345543     Document Type: Editorial

References (30)

1. Zito JM, Safer DJ, de Jong-Van Den Berg LT, Janhsen K, Fegert JM, Gardner JF, Glaeske G, Valluri SC: A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008; 2: 26
2. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief 2011; 76: 1-8
3. Food and Drug Administration Public Health Advisory, October 15, 2004: Suicidality in Children and Adolescents Being Treated with Antidepressant Medication. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108363.htm
4. Leckman JF, King RA: A developmental perspective on the controversy surrounding the use of SSRIs to treat pediatric depression. Am J Psychiatry 2007; 164: 1304-1306
5. Adegbite-ADeniyi C, Gron B, Rowles BM, Demeter CA, Findling RL: An update on antidepressant use and suicidality in pediatric depression. Expert Opin Pharmacother 2012; 13: 2119-303
6. Offidani E, Fava GA, Tomba E, Baldessarini RJ: Excessive mood-elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: systematic review. Psychother Psychosom, in press
7. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D: Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004; 158: 773-780
8. Ernst CL, Goldberg JF: Clinical features related to age at onset in bipolar disorder. J Affect Disord 2004; 82: 21-27
9. Reichart CG, Nolen WA: Earlier onset of bipolar disorder in children by antidepressants or stimulants? An hypothesis. J Affect Disor 2004; 78: 81-84
10. Lim CJ, Leckman JF, Young C, Martin A: Antidepressant-induced manic conversion: developmentally informed synthesis of the literature. Int Rev Neurobiol 2005; 65: 25-52
11. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-Analysis of randomized controlled trials. JAMA 2007; 297: 1683-1696
12. Olfson M, Marcus SC, Shaffer D: Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 2006; 63: 865-872
13. Gibbons RD, Hur K, Bhaumik DK, Mann JJ: The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006; 163: 1898-1904
14. Soeteman DI, Miller M, Kim JJ: Modeling the risks and benefits of depression treatment for children and young adults. Value Health 2012; 15: 724-729
15. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP: Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762-772
16. Jureidini JN, McHenry LB: Key opinion leaders and pediatric antidepressant overprescribing. Psychother Psychosom 2009; 78: 197-201
17. Jureidini JN, McHenry LB: Conflicted medical journals and the failure of trust. Account Res 2011; 18: 45-54
18. Fava GA: Meta-Analyses and conflict of interest. CNS Drugs 2012; 26: 93-96
19. Correll CU, Kratochvil CJ, March JS: Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiatry 2011; 72: 655-670
20. Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC: Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359: 2753-2766
21. Ginsburg GS, Kendall PC, Sakolsky D, Compton SN, Piacentini J, Albano AM, Walkup JT, Sherrill J, Coffey KA, Rynn MA, Keeton CP, McCracken JT, Bergman L, Iyengar S, Birmaher B, March J: Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol 2011; 79: 806-813
22. McBee-Strayer S, Gardner W, Kelleher K, Strange B, Heck KM, Fan L: Monitoring pediatric antidepressant use. Behav Healthc 2010; 30: 19-21
23. Aagaard L, Thirstrup S, Hansen EH: Opening the white boxes: the licensing documentation of efficacy and safety of psychotropic medicines for children. Pharmacoepidemiol Drug Saf 2009; 18: 401-411
24. Andersen SL, Navalta CP: New frontiers in developmental neuropsycho-pharmacology: can long-term therapeutic effects of drugs be optimized through carefully timed interventions? J Child Psychol Psychiatry 2011; 52: 477-504
25. Ansorge MS, Morelli E, Gingrich JA: Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 2008; 28: 199-207
26. Grzeskowiak LE, Gilbert AL, Morrison JL: Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors. J Clin Psychopharmacol 2012; 32: 615-621
27. Salisbury AL, Wisner KL, Pearlstein T, Battle CL, Stroud L, Lester BM: Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress Anxiety 2011; 28: 1008-1019
28. Pawluski JL, Rayen I, Niessen NA, Kristensen S, Van Donkelaar EL, Balthazart J, Steinbusch HW, Charlier TD: Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience 2012; 220: 131-141
29. Sass A, WOrtwein G: The effect of subchronic fluoxetine treatment on learning and memory in adolescent rats. Behav Brain Res 2012; 228: 169-175
30. Leckman JF: Whats next for developmental psychiatry? World Psychiatry, in press